TriSalus Life Sciences appoints chief commercial officer

,

TriSalus Life Sciences appoints chief commercial officer

Trevor McCaw has become chief commercial officer of TriSalus Life Sciences, an emerging immuno-oncology company committed to transforming outcomes for patients with solid tumors. This is a new position within TriSalus, reporting directly to TriSalus CEO Mary Szela. Management says McCaw will play a central role in integrating the company’s therapeutics and innovative drug-delivery systems to provide a total solution for patients.

“Trevor’s passion for taking on scientific challenges and translating them into solutions that make a difference in the lives of patients is inspiring,” Szela says. “He shares our belief in the capabilities of integrating novel therapeutics with drug delivery systems in an effort to improve outcomes for patients with solid pancreatic and liver tumors. His talents solidify our management team and his experience and the results he’s achieved as a medical device leader will serve to advance the TriSalus vision. I’m excited by and confident in Trevor’s abilities to help us realize our vision on behalf of patients.”

In this role, McCaw assumes leadership responsibility for the company’s on-market technology commercialization efforts, oversight of strategic and tactical execution of sales, upstream and downstream marketing, field clinical support and training, and oversight of the long-term strategy for integrating therapeutics with the technology business.

Trevor McCaw

McCaw was most recently president and chief commercial officer of Clerio Vision. “My life’s work has been centered on advancing innovative medical device and healthcare technologies aimed at improving patients’ lives,” he says. “I’m thrilled to be part of the TriSalus team and its belief in and willingness to develop ways to change the outcomes for those with the most intractable forms of cancer, namely solid tumors of the liver and the pancreas. Integrating novel therapeutics and device technology is such a logical, but underappreciated way in which we can make a difference in cancer care.”

In addition to his work at Clerio Vision, McCaw served as president and chief operating officer for Blueprint Clinical, where he oversaw the development and commercialization of COMPASS, a leading risk-based monitoring analytic platform for clinical trials. McCaw founded Aegis Medical Innovations of Vancouver, overseeing fundraising, operations, R&D and clinical trials of a break-through implantable cardiovascular stroke prevention device licensed from Mayo Clinic. McCaw received his bachelor of applied science in electrical computer engineering from Queen’s University, Kingston, Canada, and a master’s degree in Business from Harvard School of Business, Cambridge, Mass.